AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03119779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA-Anglus
Description: MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
Study NCT03119779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal
Description: TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
Study NCT02221310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab Ozogamicin 7.5 mg/m\^2/dose given IV over 2 hours once during conditioning
Study NCT04262037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound will be performed after induction of anesthesia and at the end of the operation with a 5-MHz curved array probe (MindrayDC-N6; Mindray; Shenzhen, China
Study NCT01353378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
Study NCT04892238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 13-C urea breath test
Description: Standard urea breath test (UBT) (HELICARB, LLC ISOCARB, reg. cert. #РЗН 2016/3773 issued by Roszdravnadzor on 29.02.2016) with 13C-carbamide of 99% purity used for the study.~Samples of exhaled air obtained before and after 20 minutes after 50 mg 13C-urea intake are analysed for 13C/12C isotope ratio with the use of infrared spectrometer IRIS.Doc (Kibion, Sweden). Delta over baseline (δ) of 13C / 12C is calculated based on the results of the initial and second samples, the results were shown in ppm (‰). The results of the test is negative if δ was \<4.0‰; test results with δ ≥4.0‰ are considered positive.
Study NCT02680236 — intervention group
Intervention type: OTHER
Intervention: Art Therapy Group
Description: Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post.
Study NCT02018991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-Eluting Stent (EES)
Description: Patients treated with EES
Study NCT02018991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting-Stent (ZES)
Description: Patients treated with ZES
Study NCT04563845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered.
Study NCT02018991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-Eluting-Stent (BES)
Description: Patients treated with BES
Study NCT00273728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
Description: hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
Study NCT01325779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: subcutaneous heparin 5000 units every 8 hours
Study NCT01325779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: subcutaneous enoxaparin 40 milligrams every 24 hours
Study NCT00907374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benazepril
Description: benazepril 10 mg orally once daily
Study NCT00907374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benazepril
Description: 40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
Study NCT04499586 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy Combined With Raltitrexed and Irinotecan
Description: Each cycle lasts 3 weeks. Raltitrexed: 3mg/m2 per week. Irinotecan : 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) per week. Radiation: 45-55Gy/25-30Fx
Study NCT00439556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplantation
Study NCT00439556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00439556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT01125111 — intervention group
Intervention type: PROCEDURE
Intervention: surgery(robot versus laparoscopy)
Study NCT03507556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple paste and induced bleeding
Study NCT03507556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Description: triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
Study NCT01944995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glasses broadband
Study NCT01944995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal CPAP
Study NCT01642238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + ASA + Bivalirudin
Description: Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Study NCT01642238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + ASA + Bivalirudin
Description: Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
Study NCT01725191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01725191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01725191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT04483024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
Study NCT04483024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
Study NCT04483024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Collagen hydrolysate and chicken extract
Description: One bottle (68mL) of collagen hydrolysate (2g) in chicken extract taken daily in the morning after meal for 24 weeks
Study NCT01068938 — intervention group
Intervention type: DEVICE
Intervention: three different perimeters: HFA, Octopus, MATRIX
Description: visual fields
Study NCT02736656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-812
Study NCT04360577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combing with electro-acupuncture at Baihui(GV20), Yintang(GV29), Neiguan(PC6), Zusanli(ST36), and Gongsun(SP4).
Study NCT03621878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization exercises -Tensioner technique
Description: Exercise aiming to lengthen the neural structure using more than one joint.
Study NCT03621878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization exercises -Slider technique
Description: Exercise aiming to slide/glide the neural structure using more than one joint.
Study NCT03621878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Electrotherapy device aiming to decrease patient's symptoms.
Study NCT02205593 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Regular follow-up and treatment WITHOUT behavioural intervention
Study NCT02205593 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Regular follow-up and treatment WITHOUT behavioural intervention
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consent (high-tech)
Description: Consent provided by an animated video with captions
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video consent (low-tech)
Description: This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAQ format consent
Description: This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question.
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent
Description: The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
Study NCT02139566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDF informed consent document
Description: A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
Study NCT04563845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered.
Study NCT02358707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ibuprofen phonophoresis
Study NCT01572129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
Study NCT01572129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in addition to the chronic daily dose of 75 mg
Study NCT02053415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil low dose
Description: 3 capsules krill oil per day
Study NCT02053415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil high dose
Description: 9 capsules krill oil per day
Study NCT04582331 — intervention group
Intervention type: OTHER
Intervention: Smartphone-based voice and self-reported symptom collection
Description: Voice samples and COVID-19 symptom inventories will be collected on participant smartphone devices. No outcomes or feedback is provided on acquired data during trial conduct but will be used for confirmatory data analysis post study
Study NCT03648021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: >50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose
Study NCT03648021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
Study NCT03290274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (fornix)
Description: Deep brain stimulation at fornix
Study NCT03290274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (Basal nucleus of Meynert)
Description: Deep brain stimulation AT Basal nucleus of Meynert
Study NCT03754270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advice in lifestyle
Description: Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
Study NCT03754270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical collar
Description: Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
Study NCT01693042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary infusion of autologous bone marrow-derived cells
Description: Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
Study NCT01743781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video
Description: view a 10-minute informational video about comprehensive eye examination
Study NCT00148109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
Study NCT00148109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
Study NCT03360695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Psychiatry Consultation (PPC)
Description: Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
Study NCT03360695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
Study NCT04159558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Experimental group will use a mobile application to help them in their self-care
Study NCT01269528 — intervention group
Intervention type: OTHER
Intervention: Methacholine Challenge Test (MCT)
Description: MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
Study NCT01269528 — intervention group
Intervention type: OTHER
Intervention: Monthly telephone contact
Description: Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
Study NCT01269528 — intervention group
Intervention type: OTHER
Intervention: Visits to the study site
Description: Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
Study NCT01269528 — intervention group
Intervention type: OTHER
Intervention: Blood Test
Description: For assessing IgE levels, Eosinophils count and cytokines levels
Study NCT01269528 — intervention group
Intervention type: OTHER
Intervention: Fractional exhaled nitric oxide
Description: Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
Study NCT01600677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized medication delivery unit
Description: The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
Study NCT01600677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
Study NCT04505891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Kidney health education will be delivered prior to discharge by trained nurse educators.
Study NCT02225626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
Study NCT02225626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
Study NCT02225626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other: standard breakfast
Description: tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
Study NCT03975218 — intervention group
Intervention type: OTHER
Intervention: Patients With Stroke
Description: In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
Study NCT00661310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug review 80+ -To reduce usage of hospital care
Description: drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
Study NCT03306589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.